We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

129 hedge funds and large institutions have $628M invested in Arena Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less capital invested

Capital invested by funds: $645M → $628M (-$16.9M)

10% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 21

2% less funds holding

Funds holding: 131129 (-2)

25% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 44

47% less call options, than puts

Call options by funds: $22.8M | Put options by funds: $43.1M

Holders
129
Holders Change
-2
Holders Change %
-1.53%
% of All Funds
3.71%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
33
Reduced
44
Closed
21
Calls
$22.8M
Puts
$43.1M
Net Calls
-$20.2M
Net Calls Change
+$4.67M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$163M +$2.17M +34,426 +1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$78.2M +$567 +9 +0%
BFA
3
BlackRock Fund Advisors
California
$45.3M -$4.12M -65,478 -8%
O
4
OppenheimerFunds
New York
$41M
State Street
5
State Street
Massachusetts
$38.9M -$3.57M -56,752 -8%
BIT
6
BlackRock Institutional Trust
California
$35.8M -$499K -7,923 -1%
DM
7
Deerfield Management
New York
$25.6M +$19.9M +315,249 +259%
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$23.8M +$2.6M +41,339 +11%
Norges Bank
9
Norges Bank
Norway
$22.6M +$13.7M +218,343 +130%
Northern Trust
10
Northern Trust
Illinois
$15.1M -$1.96M -31,075 -11%
Morgan Stanley
11
Morgan Stanley
New York
$14.3M +$8.89M +141,130 +136%
Invesco
12
Invesco
Georgia
$8.77M -$2.21M -35,059 -19%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$7.4M +$266K +4,232 +3%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$7.36M +$22.2K +352 +0.3%
TCIM
15
TIAA CREF Investment Management
New York
$6.52M +$685K +10,883 +11%
Charles Schwab
16
Charles Schwab
California
$5.58M +$2.34M +37,114 +64%
TA
17
Teachers Advisors
New York
$5.25M -$57.6K -915 -1%
Goldman Sachs
18
Goldman Sachs
New York
$4.75M -$3.68M -58,520 -42%
Group One Trading
19
Group One Trading
Illinois
$4.71M +$4.34M +68,856 +598%
CS
20
Credit Suisse
Switzerland
$4.14M +$2.2M +34,924 +98%
GC
21
Guggenheim Capital
Illinois
$3.8M -$924K -14,671 -18%
Deutsche Bank
22
Deutsche Bank
Germany
$3.77M -$70.3K -1,117 -2%
California Public Employees Retirement System
23
California Public Employees Retirement System
California
$3.73M -$56K -890 -1%
BIM
24
BlackRock Investment Management
Delaware
$3.52M -$112K -1,777 -3%
AIG
25
American International Group
New York
$3.12M -$52.8K -839 -2%

ARNA Hedge Fund Activity: Q2 2014 in Review

129 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q2 2014, worth a combined $628M — down 2.6% from $645M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ARNA and 19 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 33 added.

The largest buyer was Deerfield Management, adding an estimated $19.9M. The largest seller was BlackRock Advisors, cutting an estimated $6.18M.

  • 129 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q2 2014, down from 131 in Q1 2014.
  • Funds reported $628M of Arena Pharmaceuticals Inc stock for Q2 2014, down 2.6% quarter-over-quarter.
  • 19 funds opened new Arena Pharmaceuticals Inc positions in Q2 2014 and 21 closed out, a net change of -2 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q2 2014 was Deerfield Management, an estimated $19.9M added.
  • The largest Arena Pharmaceuticals Inc seller in Q2 2014 was BlackRock Advisors, an estimated $6.18M sold.

Based on aggregated 13F filings for Q2 2014.